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Abstract
Background: DNA polymerase h (pol h) is capable of bypassing DNA adducts produced by cisplatin or oxaliplatin
and is associated with cellular tolerance to platinum. Previous studies showed that defective pol h resulted in
enhanced cisplatin or oxaliplatin sensitivity in some cell lines. The purpose of the present study was to investigate
the role of pol h protein expression in metastatic gastric adenocarcinoma.
Methods: Four gastric adenocarcinoma cell lines were chosen to explore the relationship between pol h protein
expression and oxaliplatin sensitivity by western blotting and MTT assay. Eighty metastatic gastric adenocarcinoma
patients treated with FOLFOX or XELOX regimen as first-line chemotherapy were analyzed, corresponding
pretreatment formalin-fixed paraffin-embedded tumor tissues were used to detect pol h protein expression by
immunohistochemistry. Relationship between pol h protein expression and clinical features and outcome of these
patients was analyzed.
Results: A positive linear relationship between pol h protein expression and 48 h IC50 values of oxaliplatin in four
gastric cancer cell lines was observed. Positivity of pol h protein expression was strongly associated with poor
treatment response, as well as shorter survival at both univariate (8 versus 14 months; P < 0.001) and multivariate
(hazard ratio, 4.555; 95% confidence interval, 2.461-8.429; P < 0.001) analysis in eighty metastatic gastric
adenocarcinoma patients.
Conclusions: Our study indicates that polh is a predictive factor of treatment response and survival of metastatic
gastric adenocarcinoma patients treated with FOLFOX or XELOX as first-line chemotherapy. Therefore confirming
the value of polh in studies with prospective design is mandatory.
Background
Stomach cancer is the fourth most common cancer
worldwide, with 603,003 new cases among men and
330,290 new cases among women per year [1]. It is the
second most common cause of cancer related death
(700,000 deaths annually), with almost two-thirds of the
cases occurring in developing countries and 42% in
China alone [2]. Surgery remains the major potential
method to cure the disease; however, approximately 84%
of gastric cancer patients will develop to be an advanced
disease, with 30% of locally advanced cases, 30% meta-
static diseases at diagnosis, and 24% recurrence diseases
[3]. The literatures showed that the median survival was
only 3-4 months among advanced gastric cancer
patients without chemotherapy. The new generation of
chemotherapeutic agents, such as Oxaliplatin, can pro-
long survival in advanced gastric cancer to be 10 to 12
months; moreover, chemotherapy can also improve the
quality of life [4-12]. Therapeutic effect mainly depends
on the response of drugs to tumor during the first-line
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chemotherapy, because so far only one small phase III
study with 120 cases showed a modest survival benefit
from irinotecan monotherapy over supportive care alone
[13]. Unfortunately, due to drug resistance, only 30-50%
response rates can be achieved even though administrat-
ing new generation drugs such as docetaxel, oxaliplatin,
capecitabine, irinotecan, S1, etc to advanced gastric can-
cer patients as first-line treatment [3]. That means at
least 50% patients have to undergo ineffective treatment,
which may not only decrease the patients’ quality of life,
but also increase the economic burden. So how to pre-
dict response of chemotherapy agents in gastric cancer
is a very important scientific issue.
Oxaliplatin is the third generation platinum, playing a
vital role in chemotherapy for gastrointestinal cancer. Oxa-
liplatin-based combination regimen such as oxaliplatin plus
5-FU or 5-FU-like drug has been proven to be active in
about 40-50% of advanced gastric cancer patients [14-16].
Oxaliplatin and cisplatin share the similar mechanism, and
cause mono-adducts and intra-strand or inter-strand
cross-links in the double DNA helix that severely block
DNA synthesis [17-19]. When this happens, some path-
ways of DNA damage repair may switch on, including
nucleotide excision repair (NER), mismatch repair (MR),
homologous recombination (HR), translesion DNA synth-
esis (TLS) [20]. These adduct repairs occur primarily
through NER [21]. TLS is another alternative way to repair
these lesions, which is mainly done by DNA polymerases h
[22]. Polymeraseh(Polh), one of lesion-replicating enzymes,
incorporates the correct nucleotide over lesions such as a
platinum adduct by TLS and continues chain elongation,
whereas classical pols cannot [23]. Polh has the highest
efficacy of bypassing Pt-GG intra-strand diadducts caused
by platinum among these lesion-replicating enzymes, with
limited fidelity [23,24]. Recent experiments have shown
that the absence of polh results in a statistically significant
enhancement in cisplatin sensitivity when comparing polh-
null Xeroderma Pigmentosum-variant human fibroblasts
with polh-expressing ones [25]. This enhancement is also
observed when the cells were treated with carboplatin and
oxaliplatin [25]. Recent data show that polh mRNA level
negatively correlated with cisplatin sensitivity of non small
cell lung cancer (NSCLC) cell lines [26].
In the present study, we report for the first time the
relationship between polh protein expression and oxali-
platin sensitivity of gastric cancer cell lines and the sig-
nificance of that in predicting treatment response and




The gastric cancer cell lines, including SGC7901, AGS,
MKN45, and MGC803, were donated by Professor
Libing Song from State Key Laboratory of Oncology in
Southern China (Cancer Center of Sun yet-sen Univer-
sity). All cell lines were maintained in RPMI 1640
(Gibco) supplemented with 10% fetal bovine serum
(Gibco), except MKN 45 with 20% fetal bovine serum.
Patients and Samples
Patients in our clinical database with chemotherapy-
naïve, histologically proven metastatic advanced gastric
cancer were enrolled for the study. All patients had to
receive FOLFOX (fluorouracil, leucovorin and oxalipla-
tin) or XELOX (capecitabine and oxaliplatin) regimen as
first-line chemotherapy at Cancer Center of Sun Yat-sen
University, and formalin-fixed paraffin-embedded pre-
treatment samples under gastroscope biopsies or pallia-
tive operation were obtained. Histopathologic
characteristics were confirmed by blinded review of the
original pathology slides. The TNM classification was
used for pathologic staging, and the World Health Orga-
nization classification was used for pathologic grading.
Other inclusion criteria included age between 18-80,
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 2 or less, second line chemotherapy or
not, no radiation treatment. All patients provided writ-
ten informed consent; we obtained separate consent for
use of specimens. Study approval was obtained from
independent ethics committees at Cancer Center of Sun
Yat-Sen University. The study was undertaken in accor-
dance with the ethical standards of the World Medical
Association Declaration of Helsinki.
Follow-up and evaluations
Patients were followed up by telephone or letter com-
munication once every year for a total of 4 years. Over-
all survival was defined as the time from the date of
confirmed diagnosis to death and censored at the date
of last contact for a surviving patient. Disease response
was evaluated according to the Response Evaluation Cri-
teria in Solid Tumours (RECIST criteria) [27].
Cytotoxicity assays
Cell growth inhibition was determined by 3- (4,5-
dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide
assay (MTT assay). Briefly, cells were seeded in 96-well
plates and allowed to attach overnight. After 48 hours
of drug incubation at various concentrations (37°C),
MTT reagent (5 mg/mL, 20 μL/well) was added to each
well and incubated for an additional 4 hours. The plates
were then centrifuged (1,500 g, 5 minutes) and the
supernatant was removed. The cell pellets were dis-
solved in 200 uL DMSO. Absorbance was determined
using the Model 550 Microplate Reader (BIO-RAD,
Hercules, CA, USA) at a wavelength of 570 nm, with
background subtraction at a wavelength of 630 nm. All
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experiments were performed in triplicate. The concen-
tration required to inhibit cell growth by 50% (IC50)
was calculated from survival curves using the Bliss
method [28].
Western blotting
Cells were washed with ice-cold phosphate buffer saline
and harvested in sampling buffer [62.5 mmol/L Tris-
HCl (pH 6.8), 2% SDS, 10% glycerol, and 5% 2-h-mer-
captoethanol]. Protein concentration was determined by
Bradford assay (Bio-Rad Laboratories). Equal amounts of
proteins were applied to 7.5% polyacrylamide SDS gels
(SDS-PAGE), separated electrophoretically, and trans-
ferred onto polyvinylidene fluoride membranes. After
blocked in 5% non-fat milk in TBST buffer (10 mmol/L
Tris-HCL, 150 mmol/L NaCl, and 0.1% Tween20, pH
8.0) for 1 h at room temperature, the membrane was
incubated with anti-polh rabbit antibody (1:400;
Abcam). Polh expression was detected with horseradish
peroxidase-conjugated goat anti-rabbit IgG and
enhanced chemiluminescence. Anti-a-tubulin antibody
was used as the loading control.
ImageJ software from National Institutes of Health
(NIH) was employed to quantify protein.
Immunohistochemistry
Immunohistochemical (IHC) analysis was done to detect
polhprotein expression in 80 human gastric cancer tis-
sues. Briefly, the tissue sections were deparaffinized in
xylene at 37°C for 20 minutes and rehydrated. Endogen-
ous peroxide was blocked by incubating the sections
with 3% hydrogen peroxide in methanol for 20 minutes
at 37°C. Then the sections were submerged into 10 mM
citrate buffer (pH 6.0) and microwaved for antigenic
retrieval, followed by incubation with rabbit anti- polh
(1:100; Abcam) overnight at 4°C. After washing, tissue
sections were treated with horseradish peroxidase-
labeled secondary antibody for 30 minutes. The sections
were developed with diaminobenzidine tetrahydrochlor-
ide (DAB) and counterstained with hematoxylin.
Analysis of immunohistochemistry in our study was
carried out by two independent observers based on the
proportion of positively stained tumor cells. If there is
difference between these two observers, these slides
were reinvestigated by both investigators using a multi-
headed microscope. Tumors with more than 5% of
POLh-positive cancer cells were regarded as positive
(nucleus staining), otherwise negative.
Statistical analysis
Receiver operating characteristic (ROC) curve analysis
and Fisher’s exact test were performed to select IHC Pol-
positive value with highest accuracy. 2 × 2 table was con-
structed yielding sensitivity, specificity, positive and
negative predictive value, and accuracy was calculated as
proportion of true positive and true negative patients out
of whole patients. All statistical analyses were performed
by SPSS 15.0 statistical software package (SPSS Inc, Chi-
cago, IL, USA). P value < 0.05 was considered to be sta-
tistically significant. Kaplan-Meier analysis with log-rank
testing was used for univariate analyses. Variables show-
ing a trend for association with survival (P < 0.05) were
selected for inclusion in the final multivariate Cox pro-
portional hazards model. The relationship between polh
expression and clinicopathologic characteristics was
examined by a chi-square test and Fisher’s exact tests.
Results
Polh expression correlates with oxaliplatin sensitivity of
gastric cancer cell lines
Oxaliplatin sensitivity of four gastric cell lines (SGC7901,
AGS, MKN45, and MGC803) were detected by MTT
assay described above. Endogenous polh protein expres-
sion of four cell lines were compared with each other by
western blotting and the half maximal inhibitory concen-
tration (IC50) values of oxaliplatin for cells were shown
in Figure 1. Significant and positive correlation was
observed, as shown in Figure 2 when compared polh pro-
tein expression with IC50 values of oxaliplatin.
Patient characteristics
Eighty patients from January 2005 and July 2009 were
retrospectively analyzed. Patients had a median age of
54 (range, 26.0-79.0), with 49 males and 31 females.
Other clinical characteristics were summarized in Table
1. The response rate (CR+PR) with first-line XELOX or
FOLFOX chemotherapy was 47.5%, clinical benefit rate
(CR+PR+SD) was 77.5%. Part of these patients (23/80)
had second-line chemotherapy.
The criteria that tumor tissue with more than 5% of Polh-
positive cancer cells was defined as IHC-positive has
highest accuracy in predicting clinical benefit of first line
chemotherapy
Tumor tissues of eighty metastatic gastric cancer
patients treated with FOLFOX or XELOX regimen were
used to detect polh protein expression by Immunohisto-
chemistry (Figure 3). Because the percentage of nucleus-
staining tumor cells in all cases was no more than 10%,
we tried to select IHC Polh-positive value with highest
accuracy to predict clinical benefit of first line che-
motherapy. We defined nine IHC-positive value: ≥ 1%, ≥
2%, ≥ 3%, ≥ 4%, ≥ 5%, ≥ 6%, ≥ 7%, ≥ 8%, ≥ 9%, and con-
structed nine 2× 2 table. Table 2 is showed as an exam-
ple. Sensitivity, specificity, positive and negative
predictive value, and accuracy was calculated and used
to draw ROC curve. As showed in Table 3 and Figure 4
cut off value ≥ 5%, has highest accuracy (88.8%). So
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tumors with more than 5% of POLh-positive cancer
cells were regarded as positive (nucleus staining), other-
wise negative.
Relationship of polh expression with the clinical features
of metastatic gastric cancer
As shown in Table 4 Only 23 of 80 cases (28.75%) had
polh protein positive expression (≥ 5% Polh-positive
cancer cells), 16 of the 23 positive cases (69.56%) failed
to the treatment, in contrast, only 2 of the 57 negative
cases (3.51%) had progressed disease after FOLFOX or
XELOX chemotherapy. Polh expression strongly corre-
lated with treatment response to oxaliplatin-based che-
motherapy of metastatic gastric cancer (P < 0.001),
whereas it is not associated with age, gender, primary
sites, metastatic sites or pathologic differentiation levels.
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Figure 1 Expression analysis of POL h protein in gastric cancer cell lines by western blotting and 48 h IC50 values of oxaliplatin for
gastric cancer cells (umol/L).
Figure 2 Correlation between POL h expression and IC50 of oxaliplatin for gastric cells.
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Spearman correlation analysis was further done to
confirm the correlation between polh expression and
clinicopathologic features. Pearson contingency coeffi-
cient shown that polhexpression levels was significantly
related with treatment response (P < 0.001), likewise, no
significant correlations with other factors was obtained
(data not shown).
Relationship between polh expression and survival of
metastatic gastric cancer
Kaplan-Meier univariate survival analysis revealed that
the positive expression of polh in tumor cells and poor
treatment response were significantly associated with
shorter survival. The median survival time for polh posi-
tive and negative cases were 8 and 14 months respec-
tively, as shown in Figure 5 (log rank, P < 0.001).
Multivariate survival analysis (Cox regression model)
revealed that the expression of polh was independent
prognostic factors. The 95.0% confidence interval (CI)
for relative risk was 2.461-8.429 (Table 5). These results
indicated that the expression of polh in tumor tissue
predicted shorter survival. No relationship was observed
between the survival and the rest clinicopathological
parameters such as age, gender, primary tumor sites,
pathologic differentiation and metastatic sites.
Discussion
The present study partially revealed the role of DNA
polymeraseh as a DNA repair protein in gastric cancer
by detecting its expression in four gastric cancer cell
lines and 80 patients with metastatic gastric adenocarci-
noma who had received FOLFOX or XELOX as the first
line chemotherapy. The results showed that the expres-
sion level of polh in tumor cell lines was correlated with
the sensitivity of oxaliplatin (Figure 2). For the tumor
tissue, the positive expression only occurred in 28.75%
cases (23 out of 80), and the expression was modest.
However, strong correlation was found between polh
expression and treatment response as well as survival.
All the results demonstrated that polh positivity was an
indicator for poor treatment response and shorter survi-
val in patients of above settings.
DNA polymeraseh is coded by POLH gene which is
one of the 150 human DNA repair genes, whose defec-
tion results in Xeroderma Pigmentosum Variant (XP-V)
syndrome, manifesting highly sensitivity to UV radiation
and a trend to develop skin cancer [29-31]. Polh is an
important lesion-replicating enzyme that replicates
across pyrimidine dimers introduced by UV radiation,
avoiding high gene mutation [32]. In addition to pyrimi-
dine dimers, polh has been shown to replicate across cis-
platin cross-linked intrastrand GG sites [33]. Some
researches showed that polh expression was correlated
with sensitivity to cisplatin or oxaliplatin in XP-V human
fibroblasts cell and lung cell lines, and polh seemed to be
a treatment-response predictive marker in NSCLC
patients with cisplatin-based chemotherapy [26,27].
Less is known about the role of polh in gastric cancer.
It is the first study to detect the sensitivity of oxaliplatin
in these four gastric carcinoma cell lines (SGC7901, AGS,
MKN45, and MGC803) by MTT assay and protein
expression by western blotting. We found a significant
linear relationship between them. Our study was to some
extent consistent with the observation in lung cancer cell
lines by Paolo Ceppi et al, though what they detected
were polh mRNA level and cisplatin sensitivity [27].
Table 1 Patient characteristics (N = 80)



































CR, complete response; PR, partial response; SD, stable disease; PD,
progression disease;
BSC, best supportive care; FOLFIRI, 5-fluracil plus leucovorin plus irinotecan;
XELIRI, capecitabine plus irinotecan; DX, docitaxel plus capecitabine; TP,
paclitaxel plus cisplatin.
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Figure 3 The expression of POLh protein in advanced gastric
cancer as examined by immunohistochemistry. A. negative
expression image in tumor tissue(× 400). B. POLh protein was
detectable in the nucleus of gastric cancer cell (× 400).
Table 2 DNA polymerase h protein expression and
clinical treatment response
Clinical failure Clinical benefit Total cases
Pol h (+) 16 7 23
Pol h (-) 2 55 57
Total cases 18 62 80
≥ 5% Polh expression in tumor cells defined as positive.
Table 3 Accuracy, sensitivity, specificity, positive
predictive value, and negative predictive value according
to Polh IHC counting percent in predicting chemotherapy
response to FOLFOX or XELOX regimen
Tumor cell positive
percent, cut off
Specificity Sensitivity PPV NPV Accuracy
1% 0.419 0.889 0.308 0.929 0.525
2% 0.500 0.889 0.340 0.940 0.588
3% 0.645 0.889 0.421 0.952 0.700
4% 0.823 0.889 0.593 0.962 0.838
5% 0.887 0.889 0.696 0.965 0.888
6% 0.887 0.778 0.667 0.932 0.863
7% 0.978 0.667 0.705 0.904 0.863
8% 0 0.389 1.000 0.849 0.863
9% 0 0.111 1.000 0.795 0.800
PPV, positive predictive value; NPV, negative predictive value.
¨
Figure 4 Receiver operating characteristic curve of Polh IHC
counting in predicting chemotherapy response to FOLFOX or
XELOX regimen.
Table 4 Correlation between POL h expression and











< 60 16 37 0.690 0.797
≥ 60 7 20
Gender
Male 14 35 0.695 1.000
Female 9 22
Primary sites













CR+PR+SD 7 55 <0.001 <0.001
PD 16 2
CR, complete response; PR, partial response; SD, stable disease; PD,
progression disease.
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Then we restrospectively analyzed the expression of
polh protein in eighty metastatic advanced gastric can-
cer patients who received FOLFOX or XELOX as che-
motherapy. We firstly observed that the percentage of
polh-staining tumor cells in all 80 cases was no more
than 10%, so we defined ≥5% as IHC positive according
to the accuracy in predicting clinical benefit with
XELOX or FOLFOX chemotherapy. With this standard,
only 23 patients had positive expression, with 7 out of
62 clinical benefit cases (CR+PR+SD) from chemother-
apy and 16 out of 18 PD cases. The expression rate
between clinical benefit group (7/62, 11.3%) and PD
group (16/18, 88.9%) was significantly different (P <
0.001). This indicated that Polh positivity might predict
ineffective chemotherapy with XELOX or FOLFOX regi-
men. The result was consistent with our study in cells
that Polh expression negatively correlates with oxalipla-
tin sensitivity of gastric cancer cell lines.
We found a significant survival benefit in polh nega-
tive patients. This benefit probably came from effective
therapy of oxaliplatin, given that polh was strongly cor-
related with treatment response. It is well known that
effective chemotherapy would enhance life quality of
gastric cancer patients and improve survival; our investi-
gation can help to predict the treatment response of
oxaliplatin-based chemotherapy and survival, hence
avoid unnecessary treatment at the beginning.
There are several limitations to our study. First, This
is a retrospective study with a small number of patients.
In the preset study, no significant association between
polh expression and age, gender, primary tumor sites,
metastatic sites or pathologic differentiation was
¨
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Figure 5 Kaplan-Meier curves with univariate analysis (log-rank test) for patients with negative POLh expression versus positive POLh
expression tumors.
Table 5 Multivariate analysis of overall survival in gastric carcinoma
Factors Characteristics Hazard ratio 95%CI P value
Unfavorable Favorable
Age ≥ 60 <60 0.956 0.570-1.602 0.863
Histological grade Poorly Well/moderately 1.428 0.861-2.369 0.168
POL h positive negative 4.555 2.461-8.429 <0.001
CI, confidence interval.
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obtained on the basis of such cases number. It is possi-
ble to get significant results in some clinicopathologic
characteristics such as primary sites or pathologic differ-
entiation (P value close to 0.05), if with enough patients.
Therefore enlargeing the case number and performing
prospective trials is mandatory. Second, because the test
accuracy was calculated using the criteria defined by
ROC curve analysis, our results needed validation in an
independent cohort. Third, the expression of polh is
relatively low in gastric cancer, due to subjectivity, the
error of IHC counting could be bigger, which may influ-
ence the sensitivity and specificity when predicting treat-
ment response, so more accurate method is needed.
Forth, It is well known that platinum resistance is very
complicated, so polh, as a single parameter, is hard to
predict therapy response in an exact manner.
In spite of limitations, our study is one of the few
attempts to define criteria for in vivo chemosensitivity
of oxaliplatin-containing regimen using clinical response
as reference standard. It may be an effective and cost-
saving method to predict treatment response.
Conclusion
In conclusion, the present study demonstrated that polh
is a significant predictor of treatment response in
patients with metastatic gastric cancer receiving che-
motherapy of FOLFOX or XELOX. Such a marker
might help clinicians to choose the optimal clinical
strategy for patients with advanced gastric cancer. More-
over, the multivariate survival analysis revealed that the
expression of polh was independent prognostic factors.
The findings need to be confirmed in a larger prospec-
tive trial before application in clinical practice.
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